F
Femasys
Biotech & Life Sciences · Suwanee, United States · Founded 2004 · IPO 2021
Femasys is engaged in R&D and manufacture of medical devices for women's healthcare MoreLess
Femasys is a biomedical company that develops and commercializes non-surgical, minimally-invasive, and in-office solutions for women's health.
The company's product portfolio includes FemBloc for permanent birth control and FemVue for infertility diagnosis. These products are designed to be safer, more accessible, and more cost-effective than traditional surgical procedures. Femasys aims to address a significant unmet need in the women's health market by providing solutions that can be administered in a physician's office, reducing the need for hospitalization and general anesthesia.
The company's business model is focused on the development and commercialization of its proprietary technologies. Femasys generates revenue through the sale of its products to physicians and healthcare providers. The target market for Femasys' products includes gynecologists, obstetricians, and other healthcare professionals who specialize in women's health.
Keywords: women's health, biomedical, medical devices, non-surgical, minimally-invasive, in-office procedures, permanent birth control, infertility diagnosis, gynecologists, healthcare providers
Talent graph
Femasys's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Femasys's cap table
Sourced from Dealroom's funding and investor records.


Global footprint
Where Femasys has talent and traffic
team presence
Market sentiment
What the market is saying about Femasys
An AI-synthesized read of the highest-engagement posts about Femasys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Femasys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.